{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"606"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"636"},{"groupId":"OG001","value":"615"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles)","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W","id":"OG001","title":"Chemotherapy (SOC Treatment)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 38 months","title":"Number of Participants Who Experienced At Least One Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}